Gogo_老虎社区_美港股上老虎

adisaat
2021-12-20

Gogo

Palantir and Dewpoint Therapeutics Announce Strategic Partnership

DENVER & BOSTON, December 20, 2021--(BUSINESS WIRE)--Palantir Technologies Inc. (NYSE: PLTR), a lead

Palantir and Dewpoint Therapeutics Announce Strategic Partnership

免责声明：上述内容仅代表发帖人个人观点，不构成本平台的任何投资建议。

推荐
最新

暂无评论

热议股票

关于我们·老虎社区守则·老虎社区账号管理规范·老虎社区服务协议·老虎社区隐私政策

公司名称：北京至简风宜信息技术有限公司

违法和不良信息投诉：010-5681-3562（工作时间9:30-18:30）

邮箱：service@laohu8.com

营业执照：91110105MA01A4U55R

ICP备：京ICP备18016422号

网安备：京公网安备11010502036490

关注我们

{"i18n":{"language":"zh_CN"},"data":{"magic":2,"id":693849965,"tweetId":"693849965","gmtCreate":1640006388668,"gmtModify":1640006514873,"author":{"id":3569474549475276,"idStr":"3569474549475276","authorId":3569474549475276,"authorIdStr":"3569474549475276","name":"adisaat","avatar":"https://static.tigerbbs.com/a6863303beb81d1c605d0fa7e9761d84","vip":1,"userType":1,"introduction":"","boolIsFan":false,"boolIsHead":false,"crmLevel":3,"crmLevelSwitch":0,"individualDisplayBadges":[],"fanSize":16,"starInvestorFlag":false},"themes":[],"images":[],"coverImages":[],"extraTitle":"","html":"<html><head></head><body><p>Gogo</p></body></html>","htmlText":"<html><head></head><body><p>Gogo</p></body></html>","text":"Gogo","highlighted":1,"essential":1,"paper":1,"likeSize":4,"commentSize":1,"repostSize":0,"favoriteSize":0,"link":"https://laohu8.com/post/693849965","repostId":2192962184,"repostType":4,"repost":{"id":"2192962184","pubTimestamp":1640004360,"share":"https://www.laohu8.com/m/news/2192962184?lang=&edition=full","pubTime":"2021-12-20 20:46","market":"us","language":"en","title":"Palantir and Dewpoint Therapeutics Announce Strategic Partnership","url":"https://stock-news.laohu8.com/highlight/detail?id=2192962184","media":"Business Wire","summary":"DENVER & BOSTON, December 20, 2021--(BUSINESS WIRE)--Palantir Technologies Inc. (NYSE: PLTR), a lead","content":"<p><b>DENVER &amp; BOSTON, December 20, 2021</b>--(BUSINESS WIRE)--<a href=\"https://laohu8.com/S/PLTR\">Palantir Technologies Inc.</a> (NYSE: PLTR), a leading builder of operating systems for the modern enterprise, and Dewpoint Therapeutics (\"Dewpoint\"), the leading biomolecular condensates company, today announced a partnership for Palantir’s Foundry platform to help power Dewpoint’s efforts to discover treatments and cures for the most challenging diseases.</p>\n<p>Palantir Foundry will help to enable researchers at Dewpoint to further their understanding of condensates biology by analyzing lab data along with other data sources, including data from the published literature and databases, to identify new compounds and therapeutic approaches.</p>\n<p>Dewpoint will also use Foundry as the primary platform for its centralized knowledge repository, helping it contextualize its experimental results and prioritize the most viable outcomes. This multi-year agreement marks <a href=\"https://laohu8.com/S/AONE.U\">one</a> of Palantir’s most comprehensive partnerships with a biotechnology company.</p>\n<p>Palantir Foundry is designed to integrate disparate and siloed information sources to lead to data-driven analysis and decision making. It allows users to track lineage across systems, making it particularly suited for work in life sciences and the biotechnology sector, where data sources come from several unique and separate systems.</p>\n<p>At Dewpoint, Foundry will be able to work seamlessly with the existing systems in its laboratories to provide researchers with a comprehensive foundation for exploration and analysis.</p>\n<p>\"We think Dewpoint is changing the way the world approaches drug design by exploring new frontiers of disease biology, requiring a game changing solution that goes beyond just cloud and infrastructure to drive their R&amp;D and scale with their vision as they grow,\" said Lalarukh Haris Shaikh, Palantir’s Head of Biotech. \"We are proud to partner with Dewpoint and share their passion of working on one of the most exciting translational medicine approaches of our time.\"</p>\n<p>Foundry will help researchers make decisions around compound and target viability and streamline experiments and automate analysis by creating a digital twin of the research environment. One concrete example of Foundry’s use at Dewpoint Therapeutics is the expansion of the data foundation to include advanced genetic analysis for disease association and correlation with condensate content, empowering future discoveries.</p>\n<p>\"Key to our approach has been creating a seamless connection between our wet-lab and dry-lab capabilities, with machine learning and AI at the center. Foundry has provided us with a solid foundation for us to fully connect and operationalize our entire lab to enterprise and enable the discovery and development of new drugs,\" said Dewpoint CEO Ameet Nathwani.</p>\n<p><b>About Biomolecular Condensates</b></p>\n<p>Biomolecular condensates, formed through a process called phase separation, are membraneless droplets inside cells that facilitate molecular interactions and help cells perform vital functions. Condensates have been shown to play a critical role in key biological processes and in serious, intractable diseases across areas including neurodegeneration, cancer, inflammation, infectious disease, metabolic disease, and rare genetic disorders. The first condensates were observed more than 100 years ago. It is only in the last dozen years, though, that scientists—including Dewpoint founders Tony Hyman of the Max Planck Institute in Dresden and Rick Young of the Whitehead Institute—have begun to understand the dynamic nature and function of condensates. Dewpoint develops drugs that exploit this biology.</p>\n<p><b>About Dewpoint Therapeutics</b></p>\n<p>Dewpoint Therapeutics is the first company to apply the emerging understanding of biomolecular condensates to drug discovery. Dewpoint believes that a vast range of conditions have pathways that are regulated by condensates or arise from the dysfunction of condensates — including cancer, neurodegeneration, infectious disease, and metabolic disease. Dewpoint scientists work in Boston, Dresden, and Berlin to translate condensate biology into treatments for the toughest diseases. Learn more at dewpointx.com, and follow us on <a href=\"https://laohu8.com/S/TWTR\">Twitter</a> and LinkedIn.</p>\n<p><b>About Palantir Technologies Inc.</b></p>\n<p>Palantir Technologies Inc. builds and deploys operating systems for the modern enterprise. Additional information is available at https://www.palantir.com.</p>","source":"yahoofinance","collect":0,"html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>Palantir and Dewpoint Therapeutics Announce Strategic Partnership</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 11px; color: #7E829C; margin: 0;line-height: 11px;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\nPalantir and Dewpoint Therapeutics Announce Strategic Partnership\n</h2>\n\n<h4 class=\"meta\">\n\n\n2021-12-20 20:46 GMT+8&nbsp;&nbsp;&nbsp;<a href=https://finance.yahoo.com/news/palantir-dewpoint-therapeutics-announce-strategic-115900746.html><strong>Business Wire</strong></a>\n\n\n</h4>\n\n</header>\n<article>\n<div>\n<p>DENVER & BOSTON, December 20, 2021--(BUSINESS WIRE)--Palantir Technologies Inc. (NYSE: PLTR), a leading builder of operating systems for the modern enterprise, and Dewpoint Therapeutics (\"Dewpoint\"), ...</p>\n\n<a href=\"https://finance.yahoo.com/news/palantir-dewpoint-therapeutics-announce-strategic-115900746.html\">Web Link</a>\n\n</div>\n\n\n</article>\n</div>\n</body>\n</html>\n","type":0,"thumbnail":"","relate_stocks":{"BK4543":"AI","BK4547":"WSB热门概念","PLTR":"Palantir Technologies Inc.","BK4023":"应用软件"},"source_url":"https://finance.yahoo.com/news/palantir-dewpoint-therapeutics-announce-strategic-115900746.html","is_english":true,"share_image_url":"https://static.laohu8.com/5f26f4a48f9cb3e29be4d71d3ba8c038","article_id":"2192962184","content_text":"DENVER & BOSTON, December 20, 2021--(BUSINESS WIRE)--Palantir Technologies Inc. (NYSE: PLTR), a leading builder of operating systems for the modern enterprise, and Dewpoint Therapeutics (\"Dewpoint\"), the leading biomolecular condensates company, today announced a partnership for Palantir’s Foundry platform to help power Dewpoint’s efforts to discover treatments and cures for the most challenging diseases.\nPalantir Foundry will help to enable researchers at Dewpoint to further their understanding of condensates biology by analyzing lab data along with other data sources, including data from the published literature and databases, to identify new compounds and therapeutic approaches.\nDewpoint will also use Foundry as the primary platform for its centralized knowledge repository, helping it contextualize its experimental results and prioritize the most viable outcomes. This multi-year agreement marks one of Palantir’s most comprehensive partnerships with a biotechnology company.\nPalantir Foundry is designed to integrate disparate and siloed information sources to lead to data-driven analysis and decision making. It allows users to track lineage across systems, making it particularly suited for work in life sciences and the biotechnology sector, where data sources come from several unique and separate systems.\nAt Dewpoint, Foundry will be able to work seamlessly with the existing systems in its laboratories to provide researchers with a comprehensive foundation for exploration and analysis.\n\"We think Dewpoint is changing the way the world approaches drug design by exploring new frontiers of disease biology, requiring a game changing solution that goes beyond just cloud and infrastructure to drive their R&D and scale with their vision as they grow,\" said Lalarukh Haris Shaikh, Palantir’s Head of Biotech. \"We are proud to partner with Dewpoint and share their passion of working on one of the most exciting translational medicine approaches of our time.\"\nFoundry will help researchers make decisions around compound and target viability and streamline experiments and automate analysis by creating a digital twin of the research environment. One concrete example of Foundry’s use at Dewpoint Therapeutics is the expansion of the data foundation to include advanced genetic analysis for disease association and correlation with condensate content, empowering future discoveries.\n\"Key to our approach has been creating a seamless connection between our wet-lab and dry-lab capabilities, with machine learning and AI at the center. Foundry has provided us with a solid foundation for us to fully connect and operationalize our entire lab to enterprise and enable the discovery and development of new drugs,\" said Dewpoint CEO Ameet Nathwani.\nAbout Biomolecular Condensates\nBiomolecular condensates, formed through a process called phase separation, are membraneless droplets inside cells that facilitate molecular interactions and help cells perform vital functions. Condensates have been shown to play a critical role in key biological processes and in serious, intractable diseases across areas including neurodegeneration, cancer, inflammation, infectious disease, metabolic disease, and rare genetic disorders. The first condensates were observed more than 100 years ago. It is only in the last dozen years, though, that scientists—including Dewpoint founders Tony Hyman of the Max Planck Institute in Dresden and Rick Young of the Whitehead Institute—have begun to understand the dynamic nature and function of condensates. Dewpoint develops drugs that exploit this biology.\nAbout Dewpoint Therapeutics\nDewpoint Therapeutics is the first company to apply the emerging understanding of biomolecular condensates to drug discovery. Dewpoint believes that a vast range of conditions have pathways that are regulated by condensates or arise from the dysfunction of condensates — including cancer, neurodegeneration, infectious disease, and metabolic disease. Dewpoint scientists work in Boston, Dresden, and Berlin to translate condensate biology into treatments for the toughest diseases. Learn more at dewpointx.com, and follow us on Twitter and LinkedIn.\nAbout Palantir Technologies Inc.\nPalantir Technologies Inc. builds and deploys operating systems for the modern enterprise. Additional information is available at https://www.palantir.com.","news_type":1},"isVote":1,"tweetType":1,"viewCount":1822,"commentLimit":10,"likeStatus":false,"favoriteStatus":false,"reportStatus":false,"symbols":["GOGO"],"verified":2,"subType":0,"readableState":1,"langContent":"CN","currentLanguage":"CN","warmUpFlag":false,"orderFlag":false,"shareable":true,"causeOfNotShareable":"","featuresForAnalytics":[],"commentAndTweetFlag":false,"andRepostAutoSelectedFlag":false,"upFlag":false,"length":4,"xxTargetLangEnum":"ZH_CN"},"commentList":[],"hasMoreComment":false,"orderType":2}

Palantir and Dewpoint Therapeutics Announce Strategic Partnership

评论（1）

热议股票